drugset
drugset / Trial / NCT03877718

A Study to Assess the Efficacy and Safety of Oral CL-H1T in the Treatment of Acute Migraine Pain

NCT03877718 ↗

Phase 2 Completed 475 enrolled Charleston Laboratories, Inc
RandomizedParallel-groupDouble-blindTreatment

Summary

A Study to Assess the Efficacy and Safety of Oral CL-H1T in the Treatment of Acute Migraine Pain.

Timeline

Start
2019-02-01
Primary completion
2019-08-27
Completion
2019-08-27

Drugs

EvaluationDrugModalityDoseRoute
Subject Promethazine Small molecule 18.75 mg Oral
Subject Promethazine Small molecule 37.5 mg Oral
Subject Sumatriptan Unknown 90 mg Oral
Subject Sumatriptan Unknown 100 mg Oral

Indications

migraine disorder